New cancer drug enters human testing
NCT ID NCT07326488
Summary
This is the first study in people to test a new drug called MHB009C for patients with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and see how the body processes the drug, while also looking for early signs that it might help shrink tumors. The study will enroll about 200 adults whose cancer has progressed despite available therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center, Shanghai
Shanghai, Shanghai Municipality, 201419, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.